SLN.L Regulatory News (SLN)

DIRECTOR DISCLOSURE

17 December, 2019

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that the Company has been notified that David Horn Solomon, the Company's CEO, is subject to a private creditor action in Denmark arising as a result of his time as Managing Partner of Sund Capital, ApS from 2016 - 2018. Whilst this is a personal matter, entirely unrelated to Silence, a bankruptcy motion has been filed against David in Denmark which is due to be heard by the courts in the next few days. David is keeping the Silence Board closely informed on developments in relation to this matter and is confident that in time he can meet his financial obligations. David remains CEO of Silence.

Enquiries:

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/